Karl Jablonowski

Dr. Karl Jablonowski

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2017 in Western Journal of Emergency Medicine
Verified
Journal Article
Open access
MKMitchell Kim
Mitchell Kim
TWTaketo Watase
Taketo Watase
KJKarl Jablonowski
Karl Jablonowski
MGMedley Gatewood
Medley Gatewood
DHDaniel Henning
Daniel Henning
Many patients meeting criteria for severe sepsis are not given a sepsis-related diagnosis by emergency physicians (EP). This study 1) compares emergency department (ED) interventions and in-hospital outcomes among patients with severe sepsis, based on the presence or absence of sepsis-related diagnosis, and 2) assesses how adverse outcomes relate to three-hour sepsis bundle completion among patients fulfilling severe sepsis criteria but not given a sepsis-related diagnosis. We performed a retrospective cohort study using patients meeting criteria for severe sepsis at two urban, academic tertiary care centers from March 2015 through May 2015. We included all ED patients with the following: 1) the 1992 Consensus definition of severe sepsis, including two or more systemic inflammatory response syndrome criteria and evidence of organ dysfunction; or 2) physician diagnosis of severe sepsis or septic shock. We excluded patients transferred to or from another hospital and those <18 years old. Patients with an EP-assigned sepsis diagnosis created the "Physician Diagnosis" group; the remaining patients composed the "Consensus Criteria" group. The primary outcome was in-hospital mortality. Secondary outcomes included completed elements of the current three-hour sepsis bundle; non-elective intubation; vasopressor administration; intensive care unit (ICU) admission from the ED; and transfer to the ICU in < 24 hours. We compared proportions of each outcome between groups using the chi-square test, and we also performed a stratified analysis using chi square to assess the association between failure to complete the three-hour bundle and adverse outcomes in each group. Of 418 patients identified with severe sepsis we excluded 54, leaving 364 patients for analysis: 121 "Physician Diagnosis" and 243 "Consensus Criteria." The "Physician Diagnosis" group had a higher in-hospital mortality (12.4% vs 3.3%, P < 0.01) and compliance with the three-hour sepsis bundle (52.1% vs 20.2%, P < 0.01) compared with the "Consensus Criteria" group. An incomplete three-hour sepsis bundle was not associated with a higher incidence of death, intubation, vasopressor use, ICU admission or transfer to the ICU in <24 hours in patients without a sepsis diagnosis. "Physician Diagnosis" patients more frequently received sepsis-specific interventions and had a higher incidence of mortality. "Consensus Criteria" patients had infrequent adverse outcomes regardless of three-hour bundle compliance. EPs' sepsis diagnoses reflect risk-stratification beyond the severe sepsis criteria.

5 November 2024 in International Journal of Risk & Safety in Medicine
Verified
Journal Article
Open access
KJKarl Jablonowski
Karl Jablonowski
BHBrian Hooker
Brian Hooker
Background: Haemophilus influenzae type b (HIB) is a gram-negative pathogenic bacterium that mostly impacts the pediatric and geriatric population, sometimes resulting in permanent sequelae or death. Objective: In this study we set out to discover adverse outcomes from the thimerosal-free HibTITER® vaccine derived from a Florida Medicaid dataset spanning from January 2003 to June 2007 ( n = 277,484). Methods: HIB vaccinated children were isolated from the Florida Medicaid dataset. Using other HIB vaccines as the control, we analyzed diagnoses for statistically significant adverse outcomes related to the HibTITER® vaccine (only the strictest p-value of <0.0001 was used in analyzing this dataset). We simultaneously and independently examined the statistical significance of symptoms reported to VAERS related to HIB vaccines to corroborate our findings ( p-value significance was reported at <0.05, <0.001, and <0.0001). Results: The study revealed 19 individual ICD-9 codes positively associated ( p-value<0.0001 post Bonferroni correction) with recipients of the HibTITER® vaccine within 30-days of vaccination. Of these conditions, 14 have VAERS corroborators. The diseases span severity from mild to life-threatening and areas of respiration (e.g., asthma), gastrointestinal, otolaryngologic (e.g., common cold), dermatologic, generalized infections (e.g., tuberculosis), and other conditions. Conclusion: Incidence of 19 different medical conditions was significantly higher compared to the control group who received other HIB vaccine formulations. These results were corroborated using the VAERS database, and have profound medical implications for the estimated 35 million Americans between the ages of 16 and 33 who received the vaccine.

29 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
KJKarl Jablonowski
Karl Jablonowski
CBClayton Baker
Clayton Baker
BHBrian Hooker
Brian Hooker
We performed a secondary safety analysis of different COVID-19 vaccines from several large UK data sets. The original published studies did not perform such analyses. We assessed confidence intervals of the ratio of hazard ratios for the following published studies: Ip et al (45.7M participants) [1], Whiteley et al (45.7M) [2], Horne et al (7.6M) [3], Parker et al (427K) [4], and Hulme et al (2.7M) [5]. Our analysis reveals extreme and verifiable increased hazards associated with the Oxford/AstraZeneca ChAdOx1 COVID-19 vaccine (“AstraZeneca Product”) relative to the Pfizer-BioNTech BNT162b2 COVID-19 mRNA product (“Pfizer Product”). Significant increased hazards for the AstraZeneca Product manifested in cardiovascular disease and death. Significant increased hazards for the Pfizer Product manifested in myocarditis and pericarditis. The published primary studies, performed during the active pandemic period, promoted the “cardiovascular safety” of the COVID-19 products. However, they neglected to compare relative safety between products, which would have revealed multiple signals contrary to that narrative. Our secondary study reveals increased hazards in each type of COVID-19 product that contradict prior safety claims. The subsequent removal of the AstraZeneca Product from the market and the now-universal recognition of myocarditis risk from the Pfizer Product are consistent with our findings. The primary studies reached false conclusions that were avoidable by making comparisons of the different products, raising concerns about investigational bias.

20 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
KJKarl Jablonowski
Karl Jablonowski
BHBrian Hooker
Brian Hooker
Objectives: The investigators examined the prevalence of autism spectrum disorder (ASD) as related to the US military and as collected by the US Census Bureau’s National Survey of Children’s Health. Methods: Five questions asked of respondents allow for the inspection of ASD as it pertains to military insurance and active duty status (either past or present) of the parents. Results: Contemporary to the survey, Tricare (or other military insurance) covered children were 30.73% more likely to have an ASD diagnosis than their civilian counterparts. Children of mothers with any military service were 46.19% more likely to be diagnosed with ASD than children of non-military service mothers, with with the greatest portion diagnosed with severe autism (46.33% for mild ASD, 39.62% for moderate ASD, and 60.50% for severe ASD). Similarly, children of fathers with any military service were 42.74% more likely to be diagnosed with ASD than children of non-military service fathers, with increasing severity (37.37% for mild ASD, 45.64% for moderate ASD, and 82.73% for severe ASD). Conclusion: The severity of the results warrant an investigation, with all due haste, with domain-specific US military data that link mother-child and father-child medical records and include suspected or shared toxic exposure of either mother or father and their children.

5 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
KJKarl Jablonowski
Karl Jablonowski
BHBrian Hooker
Brian Hooker
Andersson et al. published “Aluminum-Adsorbed Vaccines and Chronic Diseases in Childhood: A Nationwide Cohort Study” with a discussion and conclusion that contradicts the data. Aluminum adjuvant safety studies are largely underwhelming, irrelevant to injectable aluminum, and are not designed to discover neurodevelopmental disease. The manuscript matches the original supplemental, where many neurodevelopmental diagnoses were deleted, but not the updated supplemental showing association to neurodevelopmental disease. Neurodevelopmental disorders such as Asperger’s syndrome, other pervasive developmental diseases, autistic disorder, and autism spectrum disorder are all found to be statistically significantly associated with a higher vaccine-derived aluminum cumulative dose.

16 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
TYThomas Yengst
Thomas Yengst
KJKarl Jablonowski
Karl Jablonowski
BHBrian Hooker
Brian Hooker
A large body of evidence implicates the exposure of susceptible individuals to acetaminophen in the etiology of ASD. We undertook this study to probe the association between ASD and a wide range of childhood diagnoses that would typically warrant acetaminophen use for treatment of pain, fever, or both. The Florida Medicaid database was utilized as the source of medical records. Associations between “acetaminophen exposure surrogates” and ASD were unexpectedly large, with odds ratios of 2.629 (2.343 to 2.949), p-value < 0.0001, for children with at least four diagnoses considered surrogates for acetaminophen use. When fever alone was inspected girls had a statistically different and greater odds ratio 3.663 (3.264 to 4.109), p-value < 0.0001, compared to boys with an odds ratio of 2.844 (2.664 to 3.036), p-value < 0.0001. The greater odds ratios for girls compared to boys appeared to be a consequence of fewer girls without ASD having acetaminophen exposure surrogates. The presence of less than four exposure surrogates was less well associated with ASD, suggesting that multiple exposure surrogates may carry the greatest relative risk of ASD, especially for girls.